cp wire

CP Wire Articles

FDA Approves Otsuka's Jynarque as First Treatment to Kidney Decline in Rapidy Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  • ADPKD, the fourth leading cause of end-stage renal disease,1,2 is a progressively debilitating genetic disease characterized by the development of fluid-filled cysts in the kidneys... read more
Tue, 04/24/18 - 06:59 pm
GSK's Trelegy Ellipta Gains New Indication in the US for the Treatment of Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced on 4/24/18 that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (... read more

Tue, 04/24/18 - 02:26 pm
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials

Celgene Corporation (NASDAQ:CELG) announced  on 4/24/18 additional phase III data analyses evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 (S1P1... read more

Tue, 04/24/18 - 09:25 am
Tarveda Therapeutics Doses First Patient in Study of Innovative Conjugate PEN-866 for Patients With Solid Tumors

Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins as a new class of potent and selective cancer medicines, announced on 4/24/18 that it... read more

Tue, 04/24/18 - 09:02 am
Surface Oncology Banks $119.5 Million With IPO and Private Placement

Surface Oncology announced on 4/23/18 the closing of its initial public offering of 7,200,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the... read more

Mon, 04/23/18 - 08:20 pm

Pages